Şevki KONÜR, Adnan ÖZKAHRAMAN, Yusuf KAYAR, Neslihan SÜRMELİ, Ramazan DERTLİ

Are noninvasive biochemical parameters an alternative toliver biopsy in patients with chronic hepatitis B?

Aim: Although there is a gold standard liver biopsy in showing the histological activity of the disease, there are contradictory results in the studies conducted for using some non-invasive methods that are alternatively biochemically calculated due to being an invasive procedure. We aimed to investigate the relationship of FIB-4, APRI, API and AAR values with histopathology in patients undergoing liver biopsy due to chronic hepatitis B virus (HBV) infection. Materials and Method: Patients with follow-up between November/2016-October/2019 with the diagnosis of chronic HBV were included. Demographic data and histopathological data were documented. Accompanying comorbid diseases, medications and previous operations were questioned. Patients were grouped as mild, moderate and advanced fibrosis according to fibrosis scoring. Sensitivity, specificity, cutt-of, AUC values of biochemical parameters were calculated between the groups. Results: A total of 151 patients, 64(42.3%) women, were included in the study. As a result of the liver biopsy; mild fibrosis was found in 73(48.3%) patients, moderate fibrosis in 33(21.8%) patients and advanced fibrosis in 45(29.9%) patients. There was a significant correlation between fibrosis level and age, liver function tests, bilirubin and albumin (p

PDF

___

1. Akarca SU. Structure, Molecular Biology, Natural Mutants and Variants of Hepatitis B Virus. J Gastroenterohepatol Special Topics 2010;3:16-23.
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virüs and hepatitis C virüs infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;4:529-38.
3. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-8.
4. Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.
5. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
6. Seo YS, Kim MY, Kim SU, et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: a multicentre, retrospective study. Liver Int 2015;35:2246-55.
7. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015. Geneva, Switzerland; 2015. pp.15-8.
8. Kim DY, Kim SU, Ahn SH, et al. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci 2009;54:1758-63.
9. Kekilli M, Tanoglu A, Sakin YS, et al. Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B? World J Gastroenterol 2015;21:5575-81.
10. Ozel Coskun BD, Dizdar OS, Baspinar O, et al. Usefulness of the Neutrophil-to-lymphocyte Ratio and Platelet Morphologic Parameters in Predicting Hepatic Fibrosis in Chronic Hepatitis C Patients Ann Clin Lab Sci 2016;46:4-8.
11. Wang J, Yan X, Yang Y, et al. A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B. Oncotarget 2017;8:59257-67.
12. Sheeth SG, Flamm SL, Gordon FD, et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998;93:44-8.
13. Poynard T, Bedossa P. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997;4:199-208.
14. Chrysantos NV, Papatheodoritis GV, Savvas S, et al. Aspartate aminotrasferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006;18:389-96.
15. Sterling RK, Lissen E, Clumerk N, et al. Development of a simple noninvazive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
16. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
17. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
18. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-8.
19. Ucar F, Sezer S, Gunes Z, et al. APRI, the FIB-4 score, and Forn’s index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2013;25:1076-81.
20. Akin MS, Yeniova AO, Demir O. Non-invasive prediction of fibrosis in chronic hepatitis B. Ann Med Res 2019;26:1588-93.
21. Sha FR, Uddin M, Abuelezz NZ, et al. Investigating the Efficiency of APRI, FIB-4, AAR and AARPRI as Noninvasive Markers for Predicting Hepatic Fibrosis in Chronic Hepatitis B Patients in Bangladesh. Open Microbiol J 2019;13:34-40.
22. Korkmaz P, Demirturk N, Batirel A, et al. Noninvasive Models to Predict Liver Fibrosis in Patients with Chronic Hepatitis B: A Study from Turkey. Hepat Mon 2017;17:60266.
23. Eminler AT, Ayyildiz T, Irak K, et al. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. Eur J Gastroenterol Hepatol 2015; 27:1361-6.
24. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 indexfor detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 2015; 61:292-302.